If you’ve read anything about popular weight-loss injection medications like Ozempic or Wegovy, you’ve likely come across the term GLP-1. Short for glucagon-like peptide-1, GLP-1 is a hormone ...

A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in ...

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among those on Wegovy than among those on Ozempic.

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Learn why experts advise against stopping and restarting GLP-1 drugs, the health risks of weight yo-yoing, and how to manage long-term weight loss safely.

A coalition of Hispanic health and public policy organizations is pushing for New Mexico’s Medicaid program to broaden its coverage of weight loss drugs as treatment for obesity. The policy change, ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

GLUCAGON-LIKE peptide-1 receptor agonists (GLP-1RA) produce greater weight loss results among women than men, a 2026 ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...